The Journal of clinical psychiatry
-
Randomized Controlled Trial Comparative Study Clinical Trial
Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients.
Both alprazolam and diazepam were superior to placebo for the treatment of the clinical anxiety syndrome throughout a four-week double-blind multiclinic trial in 976 outpatients. At the fourth-week evaluation of the 845 patients completing the study, the 326 patients receiving alprazolam showed significantly more improvement than the 344 patients receiving diazepam on all 4 anxiety rating scales utilized (Hamilton Anxiety Rating Scale, Physician's Global Assessment, Patient's Global Assessment, and Target Symptoms).
-
Randomized Controlled Trial Comparative Study Clinical Trial
Maprotiline versus imipramine and placebo in neurotic depression.
The antidepressant effect of maprotiline, a tetracyclic compound, was compared with that of imipramine in a four-week, double-blind, placebo controlled study with neurotic depressives. On all factors of the Hamilton Depression Rating Scale and on most items of the Zung Self-Rating Scales for Depression and Anxiety, maprotiline appeared slightly more effective than imipramine and showed a faster onset of action. In addition, it appeared to cause fewer anticholinergic side effects.
-
The authors report a case of acute organic brain syndrome in a patient being treated with clonidine and fluphenazine that cleared when clonidine was discontinued. Theoretical considerations of dopamine-norephinephrine interactions are discussed in the context of the drug-drug interaction.
-
Clinical Trial Controlled Clinical Trial
Clinical assessment of the safety and efficacy of lorazepam, a new benzodiazepine derivative, in the treatment of anxiety.
In a four-week double-blind study of 68 adult outpatients, lorazepam a new benzodiazepine, administered at an average total daily dosage level of 3.1 mg on a b.i.d. regimen, was clearly superior to placebo in the treatment of neurotic anxiety and its related symptoms. The lorazepam-treated group showed significantly greater improvement than the placebo-treated group (both clinically and statistically), as evidenced by the greater changes on the physician-rated Global Scale as well as by the greater changes in almost all categories on the physician-rated Hamilton Anxiety Scale and the patient-rated Lipman-Rickels 35-Item Self-Rating Scale. There were no clinically significant changes in vital signs or laboratory values and only one side effect, urinary retention (resolved without discontinuing the drug), was reported.